David Rosmarin, EADV 2021: Efficacy and Safety of Ruxolitinib Cream in Vitiligo
Dr David Rosmarin (Tufts Medical Center, Boston, MA, USA) kindly took the time to speak with touchIMMUNOLOGY about the results from the safety and efficacy studies investigating ruxolitinib cream in vitiligo. His presentation entitled ‘Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies’ was […]
John E Harris, AAD VMX 2021: Efficacy and Safety of Ruxolitinib in Vitiligo
We caught up with Prof. John E Harris (University of Massachusetts Medical School, MA, USA) to discuss the safety and efficacy results from a Phase 2 study (NCT03099304) investigating ruxolitinib cream, a JAK1/ JAK2 inhibitor, in adults with vitiligo. His abstract entitled ‘Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: 104-Week Data […]
Mehdi Rashighi, EADV 2020 – JAK inhibitors in Vitiligo
We were delighted to catch up with Mehdi Rashighi (University of Massachusetts Medical School, Boston, MA, USA) to discuss the use of JAK inhibitors in the treatment of vitiligo. Questions What are the limitations of current therapeutic approaches for vitiligo? (0:26) What is the role of the JAK pathway in the pathogenesis of vitiligo? (0:56) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!